This refers to tumors or cancers that start in the lining of your uterus, the endometrium. These can be non-cancerous (benign) or cancerous (malignant). Doctors classify them based on the type of cells involved and how abnormal they look.
Every report comes from a Lived member, sent anonymously.
Have you had Hysterectomy for Endometrial Tumors?
Endometrial tumors are growths that start in the endometrium, the inner lining of the uterus. Some are benign, such as polyps, which can grow but generally do not spread. The term most often refers to endometrial cancer (also called endometrial carcinoma), which begins when cells in the lining grow out of control. It is the most common cancer of the uterus and the most common gynecologic cancer in the United States. The usual first sign is abnormal vaginal bleeding: bleeding after menopause, bleeding between periods or a change in periods. Because bleeding tends to appear early, most endometrial cancers are found while still confined to the uterus, when treatment is very often successful. Endometrial cancer is different from uterine sarcoma, a rarer and more aggressive cancer that starts in the muscle wall of the uterus, and from cervical cancer, which starts in the cervix.
Many endometrial cancers are linked to estrogen. Estrogen makes the uterine lining grow, and progesterone balances it. When estrogen acts for long periods without enough progesterone, the lining can thicken (a condition called endometrial hyperplasia), and hyperplasia with abnormal-looking cells can progress to cancer. This explains many of the known risk factors: obesity and metabolic syndrome (body fat produces estrogen), estrogen-only hormone therapy after menopause, polycystic ovary syndrome, starting periods early or reaching menopause late, and never having been pregnant. Taking estrogen together with a progestin, rather than estrogen alone, avoids that added risk for people who still have a uterus. Risk also rises with age (the median age at diagnosis is 64) and with type 2 diabetes. Tamoxifen, a medicine used to treat or prevent breast cancer, raises risk because it acts like estrogen on the uterine lining. Some cancers, often the more aggressive serous types, do not depend on estrogen at all. Family history matters too: Lynch syndrome, an inherited defect in one of the genes that repair DNA copying errors, carries a substantially higher chance of endometrial cancer. Having risk factors does not mean someone will develop cancer, and many people with endometrial cancer have none of the classic ones.
Evaluation usually starts with a pelvic exam and a transvaginal ultrasound, in which a small probe placed in the vagina shows whether the uterine lining is thicker than expected or contains a mass. Ultrasound can raise or lower suspicion, but it cannot confirm cancer. A Pap test, which screens for cervical cancer, is not a reliable way to detect endometrial cancer. The diagnosis is made from a sample of the lining. An endometrial biopsy, done in the office, uses a thin tube passed through the cervix to draw out a small amount of tissue; it feels like strong menstrual cramps for about a minute. If the sample is too small or unclear, a dilation and curettage (D&C) scrapes tissue from the uterus, often with hysteroscopy, in which a thin camera looks directly inside. The same tissue can also show benign polyps or hyperplasia. If cancer is found, the lab reports its type and grade (how abnormal the cells look; higher grades tend to grow faster). The tumor is also tested for mismatch repair, a DNA-repair system. A defect can be a clue to Lynch syndrome, which would lead to genetic testing that matters for relatives too, and it helps predict whether immunotherapy may work. The full stage, meaning how far the cancer has spread, is usually set during surgery, with imaging such as CT or MRI when spread is suspected.
Surgery is the main treatment. Most people have a hysterectomy (removal of the uterus and cervix), usually with removal of both ovaries and fallopian tubes, and often through small incisions. Nearby lymph nodes are checked, frequently by removing only the first few nodes the cancer would drain to (sentinel lymph nodes), rather than removing many nodes, which carries a higher risk of long-term leg swelling. For cancer confined to the uterus with favorable features, surgery alone is often enough. Whether more treatment follows depends on stage, grade, cell type and molecular findings. Radiation may be given afterward to lower the chance of the cancer returning, most often as vaginal brachytherapy, in which a radiation source is placed briefly inside the vagina. Chemotherapy, typically carboplatin and paclitaxel, is used for higher-risk or advanced cancer. Immunotherapy drugs called checkpoint inhibitors, which release a brake on the immune system, are now combined with chemotherapy for many advanced or recurrent cancers. Dostarlimab (Jemperli) and pembrolizumab (Keytruda) are examples, and they work especially well when the tumor has a mismatch repair defect. Their main trade-off is that the immune system can occasionally attack healthy organs. Hysterectomy ends the ability to carry a pregnancy, and removing the ovaries before menopause brings on menopause right away, with hot flashes, vaginal dryness and longer-term bone loss. For people who want a future pregnancy and have the earliest, lowest-grade form of the most common type, surgery can be postponed while a progestin (a progesterone-like hormone) treats the cancer. A levonorgestrel intrauterine device (IUD) is the preferred form, and medroxyprogesterone or megestrol tablets are alternatives. Progestins can shrink or clear the cancer for a time, but they often do not work, and delaying surgery gives the cancer a chance to spread. This path therefore means a biopsy or D&C every 3 to 6 months, and hysterectomy is recommended once childbearing is complete because the cancer can return. Progestins are also used when surgery is not possible and for some advanced or recurrent cancers.
The outlook depends mostly on how far the cancer has spread. In US cancer statistics, about two-thirds of uterine cancers are found while still confined to the uterus, and about 95% of people in that group are alive five years later. When the cancer has reached nearby lymph nodes, that figure is about 70%, and when it has spread to distant organs, about 20%. These are group averages: cell type, grade and molecular subtype shift the picture for an individual, and some aggressive types carry more risk even when found early. After a laparoscopic, robotic or vaginal hysterectomy, most people go home the same or next day and recover fully in about 3 to 4 weeks; open surgery takes longer, about 4 to 6 weeks. Radiation and chemotherapy add months and bring fatigue and other side effects that generally ease after treatment ends. Some effects can last, including menopause symptoms when the ovaries were removed and lymphedema (persistent swelling of the legs or genitals after lymph nodes are removed). Follow-up visits with a pelvic exam are typically every 3 to 6 months for the first 2 to 3 years, when recurrence is most likely, then less often. Routine scans are generally not needed without symptoms, because most recurrences are noticed through symptoms. Heart disease is the most common cause of death among people treated for endometrial cancer, reflecting shared risk factors such as obesity and diabetes, so attention to blood pressure, blood sugar, activity and weight remains part of long-term care.
Arrange a prompt evaluation for any vaginal bleeding or spotting after menopause, bleeding between periods, a noticeable change in periods, or unusual vaginal discharge, even without blood. Most of these problems have other causes, but bleeding after menopause should always be checked, and early evaluation is what allows most endometrial cancers to be caught at a curable stage. People taking tamoxifen, and those with Lynch syndrome, should ask about their own plan for watching for these signs. After treatment, contact the care team right away rather than waiting for the next appointment if you notice signs the cancer may have come back: new bleeding from the vagina, bladder or rectum; pain in the pelvis, hips, belly or back; a persistent cough or shortness of breath; swelling in the belly or legs; or unexplained weight loss. During immunotherapy, report any new symptom promptly, since immune side effects are easier to treat early.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Endometrial Tumors is like, what's helped you, or ask the community a question.